Protective Alterations in Phase 1 and 2 Metabolism of Aflatoxin B1 by Oltipraz in Residents of Qidong, People's Republic of China
Junxiang Wang(Johns Hopkins University), Thomas W. Kensler(Johns Hopkins University), Yuequan Zhu(Beijing Luhe Hospital Affiliated to Capital Medical University), Lisa P. Jacobson(Johns Hopkins University), B-C Zhang(Cancer Institute (WIA)), Alvaro Muñoz(Johns Hopkins University), J B Wang(Johns Hopkins University), John D. Groopman(Johns Hopkins University), Patricia A. Egner(Johns Hopkins University), Geng Qian(Shanghai Cancer Institute), Xuedong Shen(Johns Hopkins University), Kathy J. Helzlsouer(Mercy Medical Center), Xia He(Jiangsu Cancer Hospital), Shuang-Yuan Kuang(Shanghai Cancer Institute), Audrey Zarba(Johns Hopkins University)
Cited by 311
Related Papers
Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival
|New England Journal of Medicine|2009|1.1k
SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity
|Nature Genetics|2001|734
Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma
|The Lancet|1992|731
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer
|Nature Genetics|2009|724
Aflatoxin: A 50-Year Odyssey of Mechanistic and Translational Toxicology
|Toxicological Sciences|2010|677